Alaunos Therapeutics (FRA:WEK) Accounts Payable & Accrued Expense : €1.75 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Alaunos Therapeutics Accounts Payable & Accrued Expense?

Alaunos Therapeutics's quarterly accounts payable & accrued expense declined from Jun. 2023 (€4.35 Mil) to Sep. 2023 (€4.09 Mil) and declined from Sep. 2023 (€4.09 Mil) to Dec. 2023 (€1.75 Mil).

Alaunos Therapeutics's annual accounts payable & accrued expense increased from Dec. 2021 (€4.89 Mil) to Dec. 2022 (€5.37 Mil) but then declined from Dec. 2022 (€5.37 Mil) to Dec. 2023 (€1.75 Mil).

Alaunos Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Alaunos Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics Accounts Payable & Accrued Expense Chart

Alaunos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

8.86

11.71

4.89

5.37

1.75

Alaunos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															5.37	5.14	4.35	4.09	1.75

Alaunos Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Alaunos Therapeutics (FRA:WEK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (FRA:WEK) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

TCRT:USA

Address

8030 El Rio Street, Houston, TX, USA, 77054

Website

https://www.alaunos.com

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Alaunos Therapeutics (FRA:WEK) Headlines

No Headlines